Navigation Links
RSB Spine, LLC, Announces Distribution Agreement with Paradigm BioDevices, Inc.

CLEVELAND, Sept. 30 /PRNewswire/ -- RSB Spine, LLC, today announced that it has signed an exclusive master distribution agreement with Paradigm BioDevices, Inc. for the U.S. market. Paradigm BioDevices was instrumental in developing the Stand Alone 360 market for ZERO-Profile(SM) ALIF implants, which is one of the fastest growing segments in the spine market. RSB Spine's growing portfolio of modular fusion products offers surgeons more choices than existing technologies in the zero profile segment of the market. Moreover, RSB Spine will introduce two new products this year, and two additional products in 2010, making the need for effective distribution critical to the ongoing success of the company.

RSB Spine Chief Executive Officer John A. Redmond said: "We are delighted with this partnership and believe that Paradigm BioDevices' proven success and expertise in this market will greatly enhance our efforts to bring unique, surgeon-friendly implants to RSB's customers. Distribution is one of the most difficult aspects of this business, and we are confident that Paradigm BioDevices will provide increased opportunities for access to quality agents and rapid sales growth."

Paradigm BioDevices, Inc., Chief Executive Officer Mike O'Neill said: "RSB's product portfolio is a truly innovative and remarkable platform that offers surgeons the ability to select material and mechanical properties that best meet their patients' individual needs. We are excited to be involved with RSB's unique products and the diverse market opportunity they afford."

RSB Spine is a privately held medical device company focused on developing innovative spinal implants with a focus on modular fusion products.

Paradigm BioDevices is a privately held manufacturer and distributor of minimally invasive tissue collection systems and novel spinal implant technologies. The company, founded in 1997, is based in Boston and has a U.S. distribution network of 68 agents and more than 250 representatives.


Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
8. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
9. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
10. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
(Date:9/27/2017)... Israel and NEW YORK , Sept. 27, ... with mobile health and big data solutions, today announced that its MyDario ... Please check your local TV listings for when The Dr. Oz Show ... ... season this month. ...
(Date:9/25/2017)... Sept. 25, 2017  EpiVax, Inc., a leader ... and immune-engineering today announced the launch of EpiVax ... of personalized therapeutic cancer vaccines. EpiVax has provided ... access to enabling technologies to the new precision ... lead EpiVax Oncology as Chief Executive Officer. Gad ...
(Date:9/22/2017)... Md. , Sept. 22, 2017  As the ... Republican Senators Bill Cassidy (R-LA) and ... Information notes that the medical device industry is in ... medical device tax, the 2.3% excise tax on medical ... But they also want covered patients, increased visits and ...
Breaking Medicine Technology:
(Date:10/12/2017)... CA (PRWEB) , ... October 12, 2017 , ... ... Cheng, are now treating sleep apnea using cutting-edge Oventus O2Vent technology. ... a serious sleep disorder characterized by frequent cessation in breathing. Oral appliances can ...
(Date:10/12/2017)... ... October 12, 2017 , ... The company has developed ... consumer and regulatory authorities worldwide. From Children’s to Adults 50+, every formula has ... highest standard. , These products are also: Gluten Free, Non-GMO, Vegan, Soy ...
(Date:10/12/2017)... ... 12, 2017 , ... The American College of Medical Informatics (ACMI) will present ... the Opening Session of AMIA’s Annual Symposium in Washington, D.C. AMIA’s Annual Symposium ... Collen, a pioneer in the field of medical informatics, this prestigious award is presented ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about the technology: ... develop to enable prevention of a major side effect of chemotherapy in children. ... pediatric patients. For cisplatin, hearing loss is FDA listed on-label as a dose ...
(Date:10/12/2017)... Malvern, PA (PRWEB) , ... October 12, 2017 , ... ... is the recipient of a 2017 Folio Magazine Eddie Digital Award for ‘Best ... New York City on October 11, 2017. , The annual award competition recognizes editorial ...
Breaking Medicine News(10 mins):